Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Microbiome
DuPont and Dutch firm pursue microbiome therapy
by Melody M. Bomgardner
February 22, 2020
| A version of this story appeared in
Volume 98, Issue 8
DuPont Nutrition & Biosciences will collaborate with the Dutch biotech firm MRM Health to discover and develop therapies based on the human gut microbiome. MRM recently raised more than $15 million from DuPont and other investors. The therapies are aimed at diseases including inflammatory bowel disease and arthritis. MRM will contribute its microbial development platform to the partnership, while DuPont will bring a selection of its live strains.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter